DGX · NYSE
Quest Diagnostics Incorporated
$242.64 +0.75 (+0.31%)
Company overview
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Exchange
- NYSE
- Market cap
- $26.8B
- Employees
- 55,000
- Headquarters
- Secaucus, NJ
- Website
- questdiagnostics.com
- CEO
- James E. Davis
- Listed
- December 17, 1996
- P/E
- 26.46
- Dividend yield
- 1.48%
Company financials
- Revenue
- $11.3B
- Gross profit
- $3.7B
- Operating income
- $1.6B
- EBITDA
- $2B
- Net income
- $1B
- EPS
- $9.17
- Total assets
- $16.7B
- Total debt
- $7B
- Gross margin
- 33.23%
- Net margin
- 9.08%
- Earnings yield
- 3.78%
No geographic segmentation.
Showing FY 2025
DGX
1D
NYSE
O242.94H244.02L240.99C242.64+0.75 (+0.31%)Vol216.19K